Shandong Kexing Bioproducts Co., Ltd.

develops recombinant or genetic engineering protein drugs, to serve the clinical treatment needs of kidney, tumor, and gastrointestinal diseases.

No.1 Chinese producer of epoetin
Recombinant Human Erythropoietin Injection (EPSINO) is the first EPO Product put in Chinese market
Domestic exclusive EPO product made without human serum albumin
Diversity of target markets including the application of renal disease,tumors,gastrointestinal tract disease, etc.
Strong R&D capabilities guided by the market
Mature domestic marketing network
High-efficient foreign sales team
Strict quality management system to ensure safety, effectiveness and stability
Improved market-oriented management team

With floor area of 1,500 square meters, its EPO and G-CSF workshops passed China’s GMP certification.
Its unit for genetically engineered drugs has floor area of over 2,000 square meters.